![David de Graaf](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David de Graaf
Direktor/Vorstandsmitglied bei Mediar Therapeutics, Inc.
Aktive Positionen von David de Graaf
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Mediar Therapeutics, Inc.
![]() Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - | - |
Independent Dir/Board Member | - | - |
Karriereverlauf von David de Graaf
Ehemalige bekannte Positionen von David de Graaf
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Comet Therapeutics, Inc.
![]() Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Vorstandsvorsitzender | 01.11.2018 | 01.07.2020 |
Präsident | 01.11.2018 | 01.07.2020 | |
Syntimmune, Inc.
![]() Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | - | 03.01.2018 |
Vorstandsvorsitzender | - | 03.01.2018 | |
Präsident | - | 03.01.2018 | |
Abcuro, Inc.
![]() Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Vorstandsvorsitzender | 07.01.2021 | - |
Selventa, Inc.
![]() Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Selventa, Inc. develops new approaches for the understanding and treatment of diseases. It focuses on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. The company was founded in 2002 by Keith O. Elliston and Noubar B. Afeyan and is headquartered in Cambridge, MA. | Vorsitzender | 02.06.2010 | - |
Technik-/Wissenschafts-/F&E-Leiter | 03.06.2010 | - | |
Präsident | 10.12.2010 | - |
Ausbildung von David de Graaf
University of Illinois | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
President | 3 |
Chief Executive Officer | 3 |
Director/Board Member | 2 |
Sektoral
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Selventa, Inc.
![]() Selventa, Inc. Miscellaneous Commercial ServicesCommercial Services Selventa, Inc. develops new approaches for the understanding and treatment of diseases. It focuses on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. The company was founded in 2002 by Keith O. Elliston and Noubar B. Afeyan and is headquartered in Cambridge, MA. | Commercial Services |
Syntimmune, Inc.
![]() Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Comet Therapeutics, Inc.
![]() Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Mediar Therapeutics, Inc.
![]() Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Abcuro, Inc.
![]() Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Commercial Services |
- Börse
- Insiders
- David de Graaf
- Erfahrung